Controlled double-blind study of the effect of rifampin on humoral and cellular immune responses in patients with pulmonary tuberculosis and in tuberculosis contacts.
D000293:Adolescent; D000328:Adult; D000917:Antibody Formation / Q000187:drug effects*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects*; D007538:Isoniazid / Q000627:therapeutic use; D007962:Leukocytes / Q000187:drug effects; D008213:Lymphocyte Activation / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D011718:Pyrazinamide / Q000627:therapeutic use; D012293:Rifampin / Q000494:pharmacology* / Q000627:therapeutic use; D012882:Skin Tests; D013307:Streptomycin / Q000627:therapeutic use; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy / Q000276:immunology*
D011718:Pyrazinamide; D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin